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ABSTRACT
In order to estimate the incidence of and risk factors for developing tuberculosis, the clinical charts of a retrospective cohort of 281 HIV-positive 
adults, who were notified to the AIDS Program of the Health Department of Brasilia in 1998, were reviewed in 2003. All the patients were treatment-
naive regarding antiretroviral therapy at the time of inclusion in the cohort. Twenty-nine patients were identified as having tuberculosis at the start of 
the study. Thirteen incident tuberculosis cases were identified during the 60 months of follow-up, with an incidence density rate of 1.24/100 person-
years. Tuberculosis incidence was highest among patients with baseline CD4+ T-lymphocyte counts ≤ 200 cells/µl who were not using antiretroviral 
therapy (incidence = 5.47; 95% CI = 2.73 to 10.94). Multivariate analysis showed that baseline CD4+ T-lymphocyte counts ≤ 200 cells/µl (adjusted 
hazard ratio [AHR] = 5.09; 95% CI = 1.27 to 20.37; p = 0.02) and non-use of antiretroviral therapy (AHR = 12.17; 95% CI = 2.6 to 56.90; 
p = 0.001) were independently associated with increased risk of tuberculosis.
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RESUMO
Para estimar a incidência e os fatores de risco para desenvolver tuberculose foram revisados em 2003 os <prontuários de uma coorte retrospectiva 
de 281 adultos infectados pelo HIV que foram notificados ao Programa de AIDS da Secretaria de Saúde de Brasília em 1998. Todos os pacientes 
eram virgens de tratamento anti-retroviral no momento da inclusão na coorte. Vinte e nove pacientes foram identificados com tuberculose na 
avaliação basal. Treze casos incidentes de tuberculose foram identificados durante os 60 meses de seguimento com densidade de incidência de 
1,24/100 pessoas-ano. A incidência de tuberculose foi maior em pacientes com contagens basal de linfócitos T CD4+ < 200 células/µl que não se 
encontravam em uso de terapia anti-retroviral 5,47 (IC95%=2,73 a 10,94). A análise multivariada demonstrou que a contagem basal de linfócitos 
T CD4+ < 200 células/µl (adjusted hazard ratio [AHR] =5,09; IC95%=1,27 to 20,37; p =0,02) e o não uso de terapia anti-retroviral (AHR=12,17; 
IC95%=2,6 to 56,90; p=0,001) estiveram independentemente associados a um risco maior de tuberculose.
Palavras-chaves: Tuberculose. Incidência. Vírus da imunodeficiência humana. Síndrome da imunodeficiência adquirida. Fatores de risco. Sobrevivência.   
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The emergence and dissemination of human immunodeficiency 
virus (HIV) in the 1980s promoted increased tuberculosis (TB) 
incidence around the world, even though in developed countries 
it had been considered under control6 9 10 25. 
TB is one of the most common causes of morbidity and 
mortality among HIV patients living in low-income countries10. 
Some estimates have shown that 30 to 60% of HIV patients 
are carriers of Mycobacterium tuberculosis with an 8 to 10% 
likelihood per year of developing the disease, whereas among 
immunocompetent individuals, the lifetime risk of TB reaches 
10%1 39. HIV increases the risk of progression from latent 
Mycobacterium tuberculosis infection, early infection or 
reinfection to active disease8 10. Previous studies have demonstrated 
that patients living with HIV/AIDS have a poor prognosis when 
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they have TB that is also associated with low CD4+ T-lymphocyte 
counts and limited access to highly active antiretroviral therapy 
(HAART)2 11 20 31 45.
The introduction of HAART has markedly changed the natural 
history of HIV infection in both developed and developing countries, 
with a notable reduction in the risk of contracting opportunistic 
infections (OI) such as Pneumocystis jirovecii pneumonia, 
Mycobacterium avium complex infection and cytomegalovirus 
retinitis35. In Brazil, access to HAART has been available since 1996, 
with the introduction of protease inhibitors and other potent drugs 
such as non-nucleoside analogues of reverse transcriptase. These 
drugs have promoted a significant reduction in overall OI, prolonged 
patient survival and improved quality of life for the patients. In addition, 
HAART has produced changes in the clinical characteristics28 and 
prognosis among HIV/TB coinfected patients1. 
In this study, we addressed the issues of incidence, survival 
and risk of TB disease among HIV-infected patients who were 
notified to the AIDS Program of the Health Department of Brasilia, 
Federal District.
PATIENTS AND METHODS
Retrospective cohort. We identified TB-naive adult patients 
among all the HIV/AIDS cases notified to the AIDS Program of the 
Health Department of Brasilia, Federal District, during 1998. The 
exclusion criteria for our study included lack of clinical records, 
healthcare at private hospitals and death within the first month 
after HIV diagnosis.
The patients were followed up for 60 months at any of 
the seven health centers in Brasilia that were able to care for 
people living with HIV/AIDS and TB. Enrolment was independent 
of disease stage and degree of immunodeficiency. Data were 
collected from clinical records according to standardized criteria 
on structured forms at registration, and again every six months 
until December 2003. AIDS was defined according to the 1993 
revised classification system for HIV infection of the Centers for 
Disease Control and Prevention7 and the Rio de Janeiro/Caracas 
criteria37. HIV and TB infection were defined in accordance with 
the Brazilian Ministry of Health guidelines for TB and HIV/AIDS. 
These guidelines included:  
Tuberculosis diagnosis: identification of Mycobacterium 
tuberculosis in cultures or acid-fast smears in sputum or other 
tissues, compatible histological findings from tissue biopsies or 
compatible clinical features13. When this last criterion was positive, 
the TB diagnosis was confirmed by means of a good response to 
specific anti-TB treatment maintained for at least two months.
The TB-free group was formed by patients without these 
features in spite of regular clinical and laboratory evaluations 
as advocated by the Brazilian National Sexually Transmitted 
Diseases/AIDS Program39, as well as absence of any clinical 
records of TB.
Hunan immunodeficiency virus diagnosis: positive 
enzyme-linked immunosorbent assay (ELISA) confirmed by either 
immunofluorescence or the western blot test37.
Initial use of HAART was defined when the patient had used 
antiretroviral drugs for at least three uninterrupted months starting 
from the cohort inception date.
Patients who did not complete the follow-up period and 
remained TB-free were censored at the last medical evaluation 
available before death, as were those who transferred to health units 
outside of the study area or who were lost from the follow-up.
Tuberculosis incidence and risk estimates. Patients who 
were diagnosed as having TB between January 1998 and December 
2003 were included in the analysis.
Incidence rate: the incidence density of TB was calculated 
by dividing the number of patients with TB by the person-years of 
follow-up of all patients at risk. Only the first detected episode of 
TB was considered for calculating the incidence rate. For a large 
number of patients, the diagnosis of HIV infection was concomitant 
with the TB diagnosis. Therefore, the incidence density was 
calculated for two groups according to the time of TB diagnosis: 
first, for patients who developed TB after the cohort inception, and 
second, for all patients including those having both HIV and TB 
diagnosis at the inception of the cohort. This approach was chosen 
because it better represented the influence of TB as a serious reason 
for focusing on persons with unknown HIV infections.
Risk estimates and survival analysis: we estimated the mean 
TB-free survival time and probability by means of a Kaplan-Meier 
curve. The incidence density and strength of association were 
estimated by means of the hazard ratio, using the Cox proportional 
hazards regression model. The patients were stratified according 
to their baseline CD4+ T-lymphocyte count (≤ 200 and > 200 
cells/µl) and the use of HAART. The Cox proportional hazards 
regression model was run in relation to sex, age, transmission risk 
group, CD4+ T-lymphocyte count, viral load and use of HAART, 
to obtain the adjusted hazard ratio. Patients with simultaneous 
diagnoses of TB and HIV infection were excluded from the survival 
and Cox proportional hazards regression analysis.
Characteristics of patients with tuberculosis. The clinical 
and epidemiological characteristics of patients during their TB 
episodes were obtained from clinical records. The characteristics 
recorded included age, sex, CD4+ T-lymphocyte count, HIV viral 
load, use of HAART and clinical presentation of TB.
Statistical analysis. Stata software (version 8; Stata 
Corporation, College Station, Texas, USA) was used for calculating 
the incidence and confidence intervals (95% CI), assuming a 
Poisson distribution of events. The survival analysis was performed 
by means of a Kaplan-Meier life table method to assess the equality of 
the survival function using the log-rank test, and by means of the Cox 
proportional hazards regression model. Variables associated with TB 
development with p < 0.5 in the crude analysis were included in the 
multivariate approach in the initial model. Variables were removed 
from the model if the value of alpha was greater than 0.05.
RESULTS
During 1998, 484 naive adult patients were reported as 
having HIV/AIDS. Of these, 173 were excluded: 85 did not have 
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clinical records available, 26 attended private hospitals and 62 
died within the first month after HIV diagnosis. Therefore, a total 
of 281 (58%) HIV-infected persons  were enrolled in the study. 
Among them, 29 were diagnosed as having simultaneous HIV and 
TB infection at the cohort inception. 
The other 252 patients enrolled in the study were 59% male. 
The main HIV transmission routes were: unprotected sex (56% 
heterosexual and 21% men who had sex with men [MSM]), 
intravenous drug use (IDU) in 14% of the patients and unknown 
cause in 9% of the patients. At diagnosis, the median age (with 
P25 – P75) was 31 years (25-37). The median (P25 – P75) 
baseline for the CD4+ T-lymphocyte count was 196 cells/µl (59-
418) and the viral load was 5.1 log RNA copies/µl (4.4-5.5).
Tuberculosis incidence. Thirteen patients were diagnosed 
as having TB during follow-up. All of the HIV-infected patients 
contributed 1048 person-years of follow-up. Those TB cases 
yielded an incidence density of 1.24 (95% CI: 0.66 to 2.12) 
events per 100 person-years of observation (PYO). The incidence 
density for the 42 coinfected patients after including 29 patients 
with simultaneous TB and HIV infection at the cohort inception 
was 4.01 (95% CI: 3.13 to 5.75) events per 100 PYO.
Among these patients, six showed clinical findings and 
radiographic images that were compatible with TB, four had 
positive sputum for acid-fast bacilli (AFB), two had positive 
cultures for Mycobacterium tuberculosis and one showed 
compatible histological findings in tissue biopsies.
Survival. Twenty-nine TB patients diagnosed at the inception 
were excluded from the survival analysis. Two-hundred and fifty-
two patients were thus included. Figure 1 shows the Kaplan-Meier 
estimates of TB-free survival proportion after diagnosis of HIV 
infection, in the overall cohort and among patients with CD4+ 
T-lymphocyte counts categorized as ≤ 200 and > 200 cells/µl, 
as stratified by the use of HAART. Survival was significantly worse 
(p < 0.001 using the log-rank test) among the patients with CD4+ 
T-lymphocyte counts ≤ 200 and among those who were not using 
HAART. Patients who showed both of these characteristics had 
the worst mean survival and highest hazard ratio for developing 
TB (Table 1). The Cox proportional hazards model including sex, 
baseline CD4+ T-lymphocyte counts, HIV baseline viral load and use 
of HAART was used to assess and correct for confounding factors. 
After adjustments were done, CD4 count ≤ 200 and non-use of HAART 
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Figure 1 - Kaplan-Meier plots of TB-free survival proportion: (A) in the overall cohort; (B) among patients stratified according to baseline CD4+ T-
lymphocyte count; (C) among patients stratified according to use of HAART; (D) among patients stratified according to baseline CD4+ T-lymphocyte 
count and use of higly active anti-retroviral therapy.
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Table 1 - Effect of baseline CD4+ T-lymphocyte cell counts and higly active anti-retroviral therapy use on      
the risk of tuberculosis disease among 252 patients living with HIV/AIDS in Brasilia, Federal District.
 Incidence rate Hazard ratio Mean survival
Baseline parameters cases per 100 PYO (95% CI) (95% CI) months (95% CI)
CD4 > 200 + HAART 0 1.0* 60.0
CD4 ≤ 200 + HAART 0.60 (0.15 – 2.37) 4.5 (1.2 – 16.4) 58.8 (57.2 – 60.4)
CD4 > 200 + non-HAART 1.26 (0.41 – 3.90) 10.1 (2.2 – 45.8) 58.2 (55.9 – 60.4)
CD4 ≤ 200 + non-HAART 5.47 (2.73 – 10.94) 44.9 (5.6 – 361.8 ) 51.5 (46.2 – 56.8)
PYO: person-years of observations, HAART: highly active antiretroviral therapy, 95% CI: 95% confidence interval.
*denominator of hazard ratio.
Table 2 - Hazard ratios for tuberculosis according to the Cox proportional hazards regression model, adjusted 
for baseline parameters among 252 patients living with HIV/AIDS in Brasilia, Federal District.
 Crude hazard ratio  Adjusted hazard ratio 
Baseline parameters (95% CI) p (95% CI) p
Male Sex 1.64 (0.50 – 5.32) 0.41  
Age < 30 years 0.88 (0.30 – 2.62) 0.82  
Transmission risk behavior    
intravenous drug use 0.50 (0.07 – 3.85) 0.51  
HIV viral load  > 5 log   1.57 (0.43 – 5.72) 0.50  
T-lymphocyte CD4 < 200 cells/µl 3.22 (0.89 – 11.71) 0.07 4.46 (1.21 – 16.35) 0.024
Non-use of antiretroviral treatment 8.06 (1.79 – 36.38) 0.007 10.07 (2.21 – 45.81) 0.003
HIV: human immnunodeficiency virus, 95% CI = 95% confidence interval.
*adjusted for variables with p < 0.5 in the crude hazard ratio analysis. 
Clinical and epidemiological characteristics of human 
immunodeficiency virus-tuberculosis coinfected patients. 
From 1998 to 2003, 42 patients were diagnosed with TB, and 
67% of them were male. The types of HIV transmission included 
heterosexual intercourse for 55% of the subjects, intravenous drug 
use for 21%, men who had sex with men for 12%, and others for 
12%. The median (P25 – P75) baseline CD4+ T-lymphocyte count 
was 99 (63-260) cells/µl and the HIV viral load was 5.4 (5.0-5.5) 
log RNA copies/µl. In Table 3, the characteristics of HIV/AIDS 
patients at the time of TB diagnosis are described. 
The TB cases were diagnosed at medians (P25 – P75) of 14 (10-21) 
and 17 (14-20) months after cohort inception among the patients who 
did and did not use HAART, respectively. In the group of patients with 
a baseline CD4+ count > 200 cells/µl, TB cases were diagnosed at a 
median (P25 – P75) of 35 (8-46) months among patients who did not 
use HAART, and no cases were identified among HAART users.
Table 3 - Characteristics of 42 HIV-TB coinfected patients diagnosed from 1998 to 2003 in Brasilia, Federal District.
 Detected at cohort  Detected during
 inception follow-up
 no = 29 no = 13
Male sex (%) 66 69
Age (median [P25 – P75] years) 34 (30 - 42) 35 (27 - 36)
Transmission risk behavior to HIV (%)  
unprotected heterosexual contacts 45 77
intravenous drug use 28  8
men who had sex with men 17  0
unknown 10 15
T-lymphocytes CD4+ count (median [P25 – P75] cells/ µl) 96 (65 - 339) 64 (34 - 99)
HIV viral load (median [P25 – P75] log RNA copies/µl) 5.3 (5.0-5.7) 5.0 (3.4 - 5.8)
Non-use of HAART (%) 100* 85
Clinical presentation of TB (%)  
pulmonary 52 62
extrapulmonary 21 23
pulmonary + extrapulmonary 27 15
Extrapulmonary TB presentation (%)  
lymph node 64 40
miliary 14 40
others** 22 20
HIV: human immnunodeficiency virus, RNA: ribonucleic acid, HAART: highly active antiretroviral therapy, TB: tuberculosis, 
*These patients did not use antiretroviral treatment, because TB diagnosis was at the same time as HIV diagnosis, ** Pleural, meningeal and 
genitourinary tuberculosis.
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DISCUSSION
Analysis of the incidence of HIV-associated TB infection in 
the HAART era has always been a difficult task. We approached 
these issues by analyzing retrospective data from newly diagnosed 
HIV-patients notified to the AIDS Program in 1998. The patients 
were from Brasilia, Federal District, which is a medium-level TB 
transmission area26 where the annual TB incidence rate in the 
general population is less than 20 cases per 100,000 inhabitants38 
Meanwhile, the national Brazilian annual incidence reaches up to 
60 cases per 100,000 inhabitants47. 
We found an overall TB incidence of 1.24 per 100 PYO. Among 
patients with advanced immunodeficiency (baseline CD4 ≤ 200 
cells/µl) who used HAART, the prognosis for not developing TB 
disease was better after six years of follow-up, with an incidence 
rate reduced by around fivefold, compared with patients who did 
not use HAART. We could not determine the time at which HAART 
use began to diminish the TB incidence rate, but in a previous 
large population study, the risk of contracting TB continued to 
decrease for six months after starting to use HAART17. 
Previous studies have reported that TB incidence among 
HIV patients varies from one country to another, depending on 
the country’s health policy regarding HAART use and the local 
TB prevalence rate. In Ethiopia, where the policy on the use of 
HAART was established in 200221 and where TB rates were high, 
the coinfection incidence reached 3.7 per 100 PYO47. However, 
in India an incidence of 6.9 per 100 PYO was reported44. India 
approved antiretroviral treatment in 200341 and  implemented it 
by 2004, and the country has continued to have high TB incidence 
for many years47. Similar numbers could be expected in India at 
present. In Europe and North America, the use of HAART was 
approved nearly a decade ago24 32 35, which has resulted in low 
reported rates of TB9 47. In Italy, the incidence was 0.79 per 100 
PYO14, a figure similar to that from the EuroSIDA cohort, which 
estimated 0.80 TB cases per 100 PYO23. The HAART Cohort 
Collaboration, an international collaborative study, reported 
0.47 TB cases per 100 PYO17. Furthermore, the Adult/Adolescent 
Spectrum of HIV Disease (ASD) project, a North American 
study, showed 0.50 TB cases per 100 PYO22. Our observations 
were thus consistent with the reported incidences in developed 
countries. However, when considering all TB cases diagnosed 
at the cohort inception, the incidence then became elevated 
by around fourfold, which may have reflected a better estimate 
if we consider the exposure risk period for Mycobacterium 
tuberculosis infection from seroconversion until HIV diagnosis. 
The number of simultaneous diagnoses of TB/HIV (69%; 29 out 
of 42) showed that the patients knew about their HIV status for 
the first time when they were also diagnosed with TB18.
Observational studies conducted both in low and in high 
TB incidence countries have shown that the risk of developing 
TB has decreased by 70 - 90% for HIV-infected individuals who 
received HAART, compared with those who were untreated4 16 22 36. 
Consequently, the incidence of HIV-associated TB has generally 
decreased in countries where HAART has become the care 
standard for HIV-infected individuals. Although HAART may 
reduce the incidence of TB, it may not completely eliminate the 
risk. Estimates have shown that early use of HAART averted TB. 
However, if HAART were started when the CD4+ T-lymphocyte 
count reached 200 cells/µl or lower, the drug regimen would only 
be able to reduce 25% of the TB cases (assuming 85% coverage 
of the population). If HAART were started with higher CD4+ 
levels, then the reduction rate for TB cases would be better46. 
Middle-income countries like Brazil that are attempting to manage 
concomitant epidemics of TB and HIV/AIDS are thus advised to 
implement broad public strategies with the aims of increasing the 
coverage and compliance and stimulating the early use of HAART 
to avert OI and TB in the course of HIV infection29. 
Unlike other OIs that occur when CD4+ T-lymphocyte counts 
drop to ≤ 200 cells/µl, active TB occurs through a broader 
spectrum of immunodeficiency19 33. The relative proportions of 
clinical forms of TB in HIV patients with almost intact immune 
function are similar to those observed in non-HIV infected patients, 
i.e. 80 to 85% presenting pulmonary forms42. Among patients with 
advanced HIV disease, pulmonary tuberculosis has decreased to 
50 to 60%, and the likelihood of extrapulmonary involvement 
rises as the immunity worsens, thus showing a predominance of 
lymphadenopathy15 43. Most of our patients presented an increased 
number of extrapulmonary TB forms, with nearly half showing 
lymph node involvement. These were compatible numbers 
considering their advanced immunodeficiency. 
Nowadays, TB diagnosis among HIV patients follows specific 
guidelines18. However, in some patients, doubt persists about clinical 
TB diagnoses in spite of using appropriate means of evaluation3. 
In the present study, patients with no microbiological confirmation 
were assumed to have had TB if the suspected clinical condition 
had improved after two months of anti-tuberculosis therapy. This 
has been possible up to now because Brazil has been considered 
to be a country with low multidrug-resistance TB prevalence47. Until 
now, there has not been an established period for confirming the 
TB diagnosis from good responses to anti-TB treatment. Reports on 
patients with difficult TB diagnoses have suggested that this period 
could vary from 3 weeks30 to 3 months5. 
TB was diagnosed earlier in HIV patients with CD4+ T-
lymphocyte counts of ≤ 200 cells/µl than in patients with higher 
CD4+ T-lymphocyte counts. Among patients with good adherence 
to antiretroviral treatment, the first TB cases appeared more than 
one year after the cohort inception. Sometimes, the immune 
reconstitution syndrome (IRIS) increases the number of TB 
cases within the first month after starting HAART use, among HIV 
patients with severe immunodeficiency17, thereby confounding the 
effectiveness of antiviral treatment for preventing TB. However, 
we did not have any patients diagnosed with TB because of IRIS 
after using HAART, since the majority of TB associated with IRIS 
developed within the first two months of HAART use (usually within 
the first 2-3 weeks12).
We have shown in this study that baseline CD4+ T-lymphocyte 
counts of ≤ 200 cells/µl and lack of HAART use were both 
independently associated with increased risk of TB, based on 
the results from our multivariate analysis. Other risk factors 
have been reported in other countries. In an adult AIDS cohort 
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in Cape Town, for individuals aged 33 years or younger, CD4+ T-
lymphocyte counts < 100 cells/µl and WHO clinical stages 3 and 4 
when HAART was first started were identified as risk factors27. In a 
study cohort in the United States, IDU, heterosexual contact, CD4+ 
T-lymphocyte counts < 100 cells/µl and lack of any antiretroviral 
therapy were important risk factors22. In Côte d’Ivoire, where TB 
incidence has been high since the 1990’s, a history of TB was an 
important risk factor for developing HIV-associated TB40 47. In 
Rio de Janeiro, positive PPD (intradermal injection of tuberculin 
antigen) was identified as an important risk factor among advanced 
immunodeficiency HIV patients36. In our study, the intermediate TB 
rates in our city and the methodological limitations of our study may 
have lowered the sensitivity for detecting other risk factors.
One important limitation was the large number of patients 
seeking medical attention after their first clinical symptoms of 
advanced immunodeficiency had occurred. This may have caused 
selection of the patients who were most vulnerable towards 
developing TB or other OIs in our study. It also yielded a limited 
estimation of the survival rates when the cohort study began at 
HIV diagnosis rather than at HIV serological conversion. This 
resulted in a much higher survival rate among patients with 
less immunodeficiency, thereby increasing the risk of latent TB 
progression to active disease. The absence of microbiological 
confirmation in some patients with TB could be another important 
limitation. Nonetheless, we could not exclude these cases, because 
of the known difficulties in confirming TB in HIV/AIDS patients, 
especially if they are in advanced stages of immunodeficiency. The 
deaths of some patients from causes other than TB, and patients 
relocating to another city were also relevant factors to consider. 
However, we believe that the impact of these factors would have 
been small because there were many critical patients still at risk 
by the end of the study period.
In conclusion, our analysis showed that HAART attenuated the 
increase in TB incidence among HIV patients, especially among 
severely immunodeficient HIV-infected individuals. Hence, the use 
of HAART diminished TB risk. Nonetheless, cases of TB appeared 
several months later in this city, which has low incidence of TB 
infection. Future prospective adult cohorts need to be established, 
with the purpose of exploring other risk factors such as social and 
economic status and TB contact in inpatient or outpatient clinical 
settings, in order to evaluate their impact on the development of 
TB among HIV patients.
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